Anemia in Chronic Kidney Disease Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Anemia in Chronic Kidney Disease Pipeline Review H1 2017” this report provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.
(EMAILWIRE.COM, July 06, 2017 ) Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means of the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness and inability to think clearly.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.
Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/anemia-in-chronic-kidney-disease-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) .
- The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001858673/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
3SBio Inc
Aevi Genomic Medicine Inc
Akebia Therapeutics Inc
Amgen Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
Biocad
CCM Duopharma Biotech Bhd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Dong-A Socio Holdings Co Ltd
FibroGen Inc
GlaxoSmithKline Plc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
JCR Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Myungmoon pharmaceutical Co Ltd
Novartis AG
Panacea Biotec Ltd
Pfizer Inc
PharmaEssentia Corp
PhytoHealth Corp
Pieris Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Xenetic Biosciences Inc
Zydus Cadila Healthcare Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001858673/discount
List of Tables
Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia) , H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Novartis AG, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001858673/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.
Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/anemia-in-chronic-kidney-disease-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) .
- The pipeline guide reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001858673/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
3SBio Inc
Aevi Genomic Medicine Inc
Akebia Therapeutics Inc
Amgen Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
Biocad
CCM Duopharma Biotech Bhd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Dong-A Socio Holdings Co Ltd
FibroGen Inc
GlaxoSmithKline Plc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
JCR Pharmaceuticals Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Myungmoon pharmaceutical Co Ltd
Novartis AG
Panacea Biotec Ltd
Pfizer Inc
PharmaEssentia Corp
PhytoHealth Corp
Pieris Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Xenetic Biosciences Inc
Zydus Cadila Healthcare Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001858673/discount
List of Tables
Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia) , H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by 3SBio Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Aevi Genomic Medicine Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Akebia Therapeutics Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Amgen Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Bayer AG, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Biocad, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CCM Duopharma Biotech Bhd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by CJ HealthCare Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by FibroGen Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by GlaxoSmithKline Plc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Japan Tobacco Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Myungmoon pharmaceutical Co Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Novartis AG, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Panacea Biotec Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pfizer Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PharmaEssentia Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by PhytoHealth Corp, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Pieris Pharmaceuticals Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Xenetic Biosciences Inc, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Dormant Projects, H1 2017
Anemia in Chronic Kidney Disease (Renal Anemia) - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001858673/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results